GSK3β, CREB, and BDNF in peripheral blood of patients with Alzheimer's disease and depression
Language English Country Great Britain, England Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
24334212
DOI
10.1016/j.pnpbp.2013.12.001
PII: S0278-5846(13)00270-4
Knihovny.cz E-resources
- Keywords
- Alzheimer's disease, BDNF, CREB, Depressive disorder, GSK3β,
- MeSH
- Alzheimer Disease blood complications psychology MeSH
- Depression blood complications psychology MeSH
- Glycogen Synthase Kinase 3 blood MeSH
- Glycogen Synthase Kinase 3 beta MeSH
- Middle Aged MeSH
- Humans MeSH
- Brain-Derived Neurotrophic Factor blood MeSH
- Neuropsychological Tests MeSH
- CREB-Binding Protein blood MeSH
- Psychiatric Status Rating Scales MeSH
- Aged MeSH
- Case-Control Studies MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- CREBBP protein, human MeSH Browser
- GSK3B protein, human MeSH Browser
- Glycogen Synthase Kinase 3 MeSH
- Glycogen Synthase Kinase 3 beta MeSH
- Brain-Derived Neurotrophic Factor MeSH
- CREB-Binding Protein MeSH
BACKGROUND: Glycogen synthase kinase-3β (GSK3β), cAMP-response element-binding protein (CREB) and brain-derived neurotrophic factor (BDNF) play critical roles in neuronal survival, synaptic plasticity and memory and participate in the pathophysiology of both depressive disorder and Alzheimer's disease (AD). METHODS: This study was designed to determine the association of GSK3β activity, CREB activity and BDNF concentration in peripheral blood of patients with AD with or without depressive symptoms and in depressive patients without AD. GSK3β activity in platelets, CREB activity in lymphocytes and BDNF concentration in plasma, platelet-rich plasma or platelets were measured in 85 AD patients (36 of whom displayed co-morbid depressive symptoms), 65 non-AD patients with depressive disorder and 96 healthy controls. AD patients were clinically assessed for stage of dementia, cognitive impairment and severity of depressive symptoms. Depressive patients were clinically assessed for severity of depression. RESULTS: We observed increased CREB activity and GSK3β activity in AD with depressive symptoms or in AD at mild stage of dementia. Decreased BDNF concentration was found in platelet-rich plasma of AD patients at moderate to severe stages of dementia or in AD without depressive symptoms. An association was revealed of the severity of cognitive impairment with the increase of GSK3β in the platelets of AD patients with mild dementia. In depressive patients, a lower concentration of phosphorylated GSK3β was associated with a higher severity of depression. Association was confirmed between severity of depression, CREB activation, and BDNF concentration in drug-naïve depressive patients. CONCLUSION: Our data demonstrated that AD is accompanied by increased CREB activity in lymphocytes and a decreased concentration of BDNF in platelet-rich plasma. The decreased BDNF concentration appears to correlate with moderate to severe stages of dementia in AD. Observation of decreased phosphorylation of GSK3β in platelets of both AD patients with depressive symptoms and depressive patients after treatment confirms the role of increased GSK3β activity in the pathophysiology of both AD and depressive disorder. Associations were confirmed between AD and platelet GSK3β activity, lymphocyte CREB activity and plasma BDNF. CREB activity and platelet BDNF concentration seems to be related to depressive disorder.
References provided by Crossref.org
Age-Dependent Alterations in Platelet Mitochondrial Respiration
Alzheimer's disease and blood-based biomarkers - potential contexts of use
